After cardiovascular disorders, multiple sclerosis (MS) is the second most common cause of mortality. Throughout the course of the projected period, the market is anticipated to rise due to the rising prevalence of multiple sclerosis. For instance, 2.8 million people worldwide were thought to have MS, according to a report in the Multiple Sclerosis Journal 2020. (35.9 Per 100,000 population). There have been discrepancies in prevalence estimates since 2013, despite the fact that MS has increased in frequency throughout the world. In the coming years, the number of ongoing clinical trials to create immunotherapeutic medications like laquinimod, ozanimod, and ponesimod is anticipated to drive the global immunomodulators market. In addition, it is anticipated that the rising demand for immunomodulators would be fueled by the growing need to treat autoimmune illnesses such rheumatoid arthritis. For instance, the British Association for Global Immunomodulators estimates that in 2018, 400,000 people in the U.K. had rheumatoid arthritis, and four million people had an autoimmune disease.
Coherent Market Insights projects that the market for Immunomodulators is anticipated to reach US$ 156378.2 million by 2028, at a CAGR of 7.9% over the forecast period, from an estimated value of US$ 91850.0 million in 2021. (2021–2028).
Key Players in the Immunomodulators industry:
1. F. Hoffmann-La Roche Ltd.
The company was established in 1896 and is headquartered in Basel, Switzerland. The business creates medications and diagnostic tools to treat serious ailments. Roche declared in March 2021 that it would buy GenMark Diagnostics for $1.8 billion. With the FDA's clearance of its high-volume Sars-CoV-2 diagnostic test in March 2020, Roche Diagnostics' division achieved a key milestone.
2. Biogen Inc.
The company was established in 1978 and is headquartered in Cambridge, Massachusetts, United States. The business specialises in the discovery, development, and distribution of therapeutics for the worldwide treatment of neurological illnesses. In order to create drugs for neurological and neuromuscular illnesses, Biogen and Sangamo Therapeutics established a global licencing agreement in February 2020.
3. Novartis AG
Novartis AG was founded in March 1996 and has offices in Basel, Switzerland, and Cambridge, Massachusetts, in the United States. Prescription drugs, over-the-counter drugs, immunisations, tests, eyeglasses, and veterinary medicine are all covered by Novartis. Handling, Marketing, Operations, and Research are a few of the activities that Novartis directly performs through its companies.
4. Teva Pharmaceutical Industries Ltd.
The corporation, founded in 1901, has its headquarters in Tel Aviv, Israel. Although its primary area of competence is in generic drugs, it also has some supplementary business interests in active pharmaceutical ingredients and, to a lesser extent, proprietary drugs. The aggressive climate targets set by Teva will have received external validation on January 19, 2023, according to the Science Based Targets initiative (SBTi). The federal opioids deal will move forward, Teva stated on January 9th, 2023, after getting broad backing from the states.
5. Johnson & Johnson
Johnson & Johnson, which was established in 1886, has its corporate headquarters in New Brunswick, New Jersey. Johnson & Johnson manufactures consumer products, prescription drugs, and medical devices. In November 2021, the business stated that it would divide into two publicly traded businesses, one specialising on consumer goods and the other in medicines and medical technologies. The business asserted that sales of its Covid-19 vaccination reached a $100 million total during the first quarter of April 2021. Johnson & Johnson paid $16.6 billion to acquire Abiomed Inc. in November 2022.
6. Eli Lilly and Company
With its corporate headquarters in Indianapolis, Indiana, the company was founded in 1876. A company in the healthcare industry called Eli Lilly and Company (Lilly) is dedicated to the discovery, advancement, and marketing of pharmaceuticals for use in treating people. Disarm Therapeutics, which offers state-of-the-art therapies for axonal degeneration, declared in October 2020 that Lilly will purchase it. The business will reportedly focus on creating medications for autoimmune disorders, diabetes, obesity, and Alzheimer's in 2023.
7. Pfizer Inc.
The company was established in 1849, and Manhattan, New York City, serves as its headquarters. The medical areas of immunology, cancer, the heart, endocrinology, and neurology are all served by Pfizer through the discovery and production of drugs and vaccines. Amplyx Pharmaceuticals and the antifungal medication fosmanogepix were acquired by Pfizer in April 2021. (APX001). In October 2022, the company successfully purchased Biohaven Pharma and its calcitonin gene-related peptide programmes
Definition: In order to help your body respond to a sickness or illness, an immunomodulator is a medicine that alters or modulates the immune system.
